Cargando…

Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis

BACKGROUND: Early prediction of response to neoadjuvant chemotherapy (NACT) is important to aid personalized treatment in osteosarcoma. Diffusion-weighted Intravoxel Incoherent Motion (IVIM) MRI was used to evaluate the predictive value for response to NACT and survival outcome in osteosarcoma. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Baidya Kayal, Esha, Bakhshi, Sameer, Kandasamy, Devasenathipathy, Sharma, Mehar Chand, Khan, Shah Alam, Kumar, Venkatesan Sampath, Khare, Kedar, Sharma, Raju, Mehndiratta, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795762/
https://www.ncbi.nlm.nih.gov/pubmed/36575510
http://dx.doi.org/10.1186/s12967-022-03838-1
_version_ 1784860330589945856
author Baidya Kayal, Esha
Bakhshi, Sameer
Kandasamy, Devasenathipathy
Sharma, Mehar Chand
Khan, Shah Alam
Kumar, Venkatesan Sampath
Khare, Kedar
Sharma, Raju
Mehndiratta, Amit
author_facet Baidya Kayal, Esha
Bakhshi, Sameer
Kandasamy, Devasenathipathy
Sharma, Mehar Chand
Khan, Shah Alam
Kumar, Venkatesan Sampath
Khare, Kedar
Sharma, Raju
Mehndiratta, Amit
author_sort Baidya Kayal, Esha
collection PubMed
description BACKGROUND: Early prediction of response to neoadjuvant chemotherapy (NACT) is important to aid personalized treatment in osteosarcoma. Diffusion-weighted Intravoxel Incoherent Motion (IVIM) MRI was used to evaluate the predictive value for response to NACT and survival outcome in osteosarcoma. METHODS: Total fifty-five patients with biopsy-proven osteosarcoma were recruited prospectively, among them 35 patients were further analysed. Patients underwent 3 cycles of NACT (Cisplatin + Doxorubicin) followed by surgery and response adapted adjuvant chemotherapy. Treatment outcomes were histopathological response to NACT (good-response ≥ 50% necrosis and poor-response < 50% necrosis) and survival outcome (event-free survival (EFS) and overall survival (OS)). IVIM MRI was acquired at 1.5T at baseline (t0), after 1-cycle (t1) and after 3-cycles (t2) of NACT. Quantitative IVIM parameters (D, D*, f & D*.f) were estimated using advanced state-of-the-art spatial penalty based IVIM analysis method bi-exponential model with total-variation penalty function (BETV) at 3 time-points and histogram analysis was performed. RESULTS: Good-responders: Poor-responders ratio was 13 (37%):22 (63%). EFS and OS were 31% and 69% with 16.27 and 25.9 months of median duration respectively. For predicting poor-response to NACT, IVIM parameters showed AUC = 0.87, Sensitivity = 86%, Specificity = 77% at t0, and AUC = 0.96, Sensitivity = 86%, Specificity = 100% at t1. Multivariate Cox regression analysis showed smaller tumour volume (HR = 1.002, p = 0.001) higher ADC-25(th)-percentile (HR = 0.047, p = 0.005) & D-Mean (HR = 0.1, p = 0.023) and lower D*-Mean (HR = 1.052, p = 0.039) were independent predictors of longer EFS (log-rank p-values: 0.054, 0.0034, 0.0017, 0.0019 respectively) and non-metastatic disease (HR = 4.33, p < 10(–3)), smaller tumour-volume (HR = 1.001, p = 0.042), lower D*-Mean (HR = 1.045, p = 0.056) and higher D*.f-skewness (HR = 0.544, p = 0.048) were independent predictors of longer OS (log-rank p-values: < 10(–3), 0.07, < 10(–3), 0.019 respectively). CONCLUSION: IVIM parameters obtained with a 1.5T scanner along with novel BETV method and their histogram analysis indicating tumour heterogeneity were informative in characterizing NACT response and survival outcome in osteosarcoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03838-1.
format Online
Article
Text
id pubmed-9795762
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97957622022-12-29 Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis Baidya Kayal, Esha Bakhshi, Sameer Kandasamy, Devasenathipathy Sharma, Mehar Chand Khan, Shah Alam Kumar, Venkatesan Sampath Khare, Kedar Sharma, Raju Mehndiratta, Amit J Transl Med Research BACKGROUND: Early prediction of response to neoadjuvant chemotherapy (NACT) is important to aid personalized treatment in osteosarcoma. Diffusion-weighted Intravoxel Incoherent Motion (IVIM) MRI was used to evaluate the predictive value for response to NACT and survival outcome in osteosarcoma. METHODS: Total fifty-five patients with biopsy-proven osteosarcoma were recruited prospectively, among them 35 patients were further analysed. Patients underwent 3 cycles of NACT (Cisplatin + Doxorubicin) followed by surgery and response adapted adjuvant chemotherapy. Treatment outcomes were histopathological response to NACT (good-response ≥ 50% necrosis and poor-response < 50% necrosis) and survival outcome (event-free survival (EFS) and overall survival (OS)). IVIM MRI was acquired at 1.5T at baseline (t0), after 1-cycle (t1) and after 3-cycles (t2) of NACT. Quantitative IVIM parameters (D, D*, f & D*.f) were estimated using advanced state-of-the-art spatial penalty based IVIM analysis method bi-exponential model with total-variation penalty function (BETV) at 3 time-points and histogram analysis was performed. RESULTS: Good-responders: Poor-responders ratio was 13 (37%):22 (63%). EFS and OS were 31% and 69% with 16.27 and 25.9 months of median duration respectively. For predicting poor-response to NACT, IVIM parameters showed AUC = 0.87, Sensitivity = 86%, Specificity = 77% at t0, and AUC = 0.96, Sensitivity = 86%, Specificity = 100% at t1. Multivariate Cox regression analysis showed smaller tumour volume (HR = 1.002, p = 0.001) higher ADC-25(th)-percentile (HR = 0.047, p = 0.005) & D-Mean (HR = 0.1, p = 0.023) and lower D*-Mean (HR = 1.052, p = 0.039) were independent predictors of longer EFS (log-rank p-values: 0.054, 0.0034, 0.0017, 0.0019 respectively) and non-metastatic disease (HR = 4.33, p < 10(–3)), smaller tumour-volume (HR = 1.001, p = 0.042), lower D*-Mean (HR = 1.045, p = 0.056) and higher D*.f-skewness (HR = 0.544, p = 0.048) were independent predictors of longer OS (log-rank p-values: < 10(–3), 0.07, < 10(–3), 0.019 respectively). CONCLUSION: IVIM parameters obtained with a 1.5T scanner along with novel BETV method and their histogram analysis indicating tumour heterogeneity were informative in characterizing NACT response and survival outcome in osteosarcoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03838-1. BioMed Central 2022-12-27 /pmc/articles/PMC9795762/ /pubmed/36575510 http://dx.doi.org/10.1186/s12967-022-03838-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Baidya Kayal, Esha
Bakhshi, Sameer
Kandasamy, Devasenathipathy
Sharma, Mehar Chand
Khan, Shah Alam
Kumar, Venkatesan Sampath
Khare, Kedar
Sharma, Raju
Mehndiratta, Amit
Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis
title Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis
title_full Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis
title_fullStr Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis
title_full_unstemmed Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis
title_short Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis
title_sort non-invasive intravoxel incoherent motion mri in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795762/
https://www.ncbi.nlm.nih.gov/pubmed/36575510
http://dx.doi.org/10.1186/s12967-022-03838-1
work_keys_str_mv AT baidyakayalesha noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis
AT bakhshisameer noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis
AT kandasamydevasenathipathy noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis
AT sharmameharchand noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis
AT khanshahalam noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis
AT kumarvenkatesansampath noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis
AT kharekedar noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis
AT sharmaraju noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis
AT mehndirattaamit noninvasiveintravoxelincoherentmotionmriinpredictionofhistopathologicalresponsetoneoadjuvantchemotherapyandsurvivaloutcomeinosteosarcomaatthetimeofdiagnosis